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Context: Thyroid hormone use is common in older populations, but the frequency of over- or
under-replacement is debated.
Objective: We sought to describe the frequency of and factors associated with thyroid hormone
over- or under-replacement in a population of older men and women.
Design: Participants were 3678 U.S. community dwelling individuals aged 65 yr or older enrolled
in the Cardiovascular Health Study who had thyroid function tests in 1989–1990. Thyroid hormone
users (n  339) were identified and classified into low TSH (0.45 mU/liter), euthyroid (0.45–4.5
mU/liter), and high TSH (4.5 mU/liter).
Results: Of the 339 thyroid hormone users, 41% had a low TSH, 16% had a high TSH, and 43% were
in the euthyroid range. In multivariable analyses, lower weight (P  0.001) was independently asso-
ciated with low TSH status. For every 10 kg lower weight, the likelihood of having low TSH increased
by 65% odd ratio (OR) 1.65; 95% confidence interval (CI) 1.31–2.07. Those with renal insufficiency
wereless likelytohavelowTSHlevels (P0.02).Thepresenceofdiabeteswasindependentlyassociated
with having low (OR 3.35; 95% CI 1.46–7.65) and high TSH levels (OR 2.66; 95% CI 1.14–6.21).
Conclusions: There is a very high prevalence of thyroid function testing abnormalities in older
people taking thyroid hormone preparations, particularly in those of low weight or with diabetes.
Because of potential adverse cardiovascular and skeletal effects from over-replacement, older
people represent a key population for increased TSH monitoring on therapy. (J Clin Endocrinol
Metab 94: 1342–1345, 2009)
The prevalence of thyroid function testing abnormalities inthose taking thyroid hormone preparations may be high,
with levels in the euthyroid range present in only 40 – 60% (1,
2). Factors that contribute to the increased risk of over- or
under-replacement have not been defined, despite the clinical
importance of identifying at-risk patients. We conducted an
analysis of individuals taking thyroid hormone preparations
who were enrolled in a population-based, longitudinal study
of community dwelling individuals aged 65 yr and older. Our
goals were to define the prevalence of thyroid function testing
abnormalities, and to determine the relationship between so-
ciodemographical factors, comorbidities, pharmacotherapy,
and over- or under-replacement in this population.
Subjects and Methods
These analyses are based on data from the Cardiovascular Health Study
(3). Enrollment of an original cohort of 5201 adults occurred from
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1989–1990. The baseline visit included a medical history, physical ex-
amination, assessment of health status, and phlebotomy. The institu-
tional review boards of all study sites and the coordinating center at the
University of Washington in Seattle approved the study.
Serum TSH concentration was measured using a chemiluminescent
immunometric assay (LumaTag hTSH; Nichols Institute, San Juan Cap-
istrano, CA) with a functional sensitivity of 0.008 mU/liter on a sub-
sample of baseline samples from 3678 individuals from the original co-
hort, as described previously (4). Free T4 concentrations were measured
with a direct, monoclonal antibody assay (Amerlex-MAB; Amersham
International, Buckinghamshire, UK) in individuals with serum TSH
levels less than 0.10 or more than 4.50 mU/liter, for the 95% of samples
with sufficient serum for this additional test.
Within this subgroup of 3678 individuals with thyroid function tests,
there were 339 who were taking thyroid hormone preparations. None of
these individuals had a history of thyroid cancer. For data analysis, these
339 individuals were classified into one of three groups: low TSH (TSH 
0.44 mU/liter), euthyroidism (TSH 0.45–4.49 mU/liter), and high TSH
(TSH 4.5 mU/liter). We performed an additional classification in 321
individuals into five categories: overt hyperthyroidism (TSH 0.10 mU/
liter plus high freeT4); subclinical hyperthyroidism (TSH 0.11–0.44 mU/
liter or 0.10 U/liter plus normal free T4); euthyroidism (TSH 0.45–4.50
mU/liter); subclinical hypothyroidism (TSH 4.51–19.9 mU/liter plus
normal free T4 level); or overt hypothyroidism (TSH 20 mU/liter or
4.50 mU/liter plus low free T4). There were 18 individuals that could
not be placed into one of these categories and were excluded: two whose
testing suggested recent nonadherence (low TSH and low free T4), two
whose testing suggested a recent dose increase (high TSH and high free
T4), and 14 with either TSH less than or equal to 0.10 mU/liter or elevated
TSH without free T4 level.
Statistical analysis
Baseline characteristics were summarized according to thyroid status
and compared against those in the euthyroid group using a t test or 2 test.
Multivariable logistical regression models comparing each abnormal
TSH group (low or high) with the euthyroid group were performed in the
333 individuals who could be identified as taking either T4 alone or a T4
plus T3 preparation. We included age and sex in all models, and added
other covariates, if significant, in stages stage 1, sociodemographical
factors: body mass index, weight, smoking, race, education, and income;
stage 2, comorbidities: diabetes, cancer, coronary heart disease, conges-
tive heart failure, renal insufficiency, and lung disease; and stage 3, med-
ications: oral steroids, -blockers, lithium, and thyroid hormone prep-
aration type, retaining factors that were statistically significant (P 
0.05) in the final model. All models were repeated in those using T4 alone
preparations to reflect current prescribing practices. Analyses were done
using STATA version 9 (StataCorp LP, College Station, TX).
Results
Of the 3678 individuals with thyroid function testing, 339
(9.2%) were taking a thyroid hormone preparation. In these 339
thyroid hormone users, 41.0% had a low TSH, 16.2% had a high
TSH, and 42.8% were in the euthyroid range. The use of prep-
arations containing both T4 and T3 was common, at 26%,
though their use did not differ by thyroid category. Ages were
similar across all thyroid status categories, with a mean age of
72.9 yr. There were more females in the low TSH group (87.8%)
than the euthyroid group (78.6%; P  0.03). Those with a low
TSH had a lower weight and body mass index (65.3 vs. 72.2 kg,
P  0.001; 25.5 vs. 27.1 kg/m2, P  0.006), had fewer medical
diagnoses (P  0.05), and were taking fewer prescription med-
ications (P  0.02) than those in the euthyroid group.
In multivariable-adjusted models, lower weight, diabetes,
and lack of renal insufficiency were independently associated
with low TSH status (Table 1). For every 10 kg lower weight, the
likelihood of having low TSH increased by 65%. Those with
diabetes were more likely and those with renal insufficiency were
less likely to have low TSH levels. When we included only T4
users in our models, results were quantitatively similar. Estrogen
use was not an independent predictor of low TSH in a model in
women only. Diabetes was the only statistically significant pre-
dictor of high TSH status. This association decreased in magni-
tude and lost statistical significance in the smaller group of those
taking only T4 preparations.
We also sought to classify further the thyroid hormone users
into categories that accounted for free T4 levels, in the 321 in-
dividuals in whom we could perform this classification (Fig. 1A).
When we examined specific preparations (Fig. 1, B and C), the
prevalence of euthyroidism was similar to the overall group.
Discussion
In a cohort study of community dwelling individuals aged 65 yr
and older, we report a low prevalence of thyroid function tests in
the euthyroid range in those taking thyroid hormone prepara-
tions, at only 43%. The high prevalence of over-replacement
TABLE 1. Risk factor associations of low TSH status and high TSH status, each compared with euthyroid group, in thyroid
hormone preparation users
All preparations T4 only preparations
OR CI P value OR CI P value
Low TSH status
Characteristics
Age (yr) 0.98 0.93–1.03 0.37 0.99 0.94–1.05 0.78
Male sex 1.05 0.49–2.24 0.90 1.00 0.40–2.48 0.99
Weight (per 10 kg decrease) 1.65 1.31–2.07 0.001 1.53 1.19–1.98 0.001
Diabetes 3.35 1.46–7.65 0.004 2.94 1.26–6.82 0.01
Renal insufficiency 0.21 0.06–0.74 0.02 0.26 0.07–0.94 0.04
High TSH status
Characteristics
Age (yr) 1.03 0.97–1.09 0.35 1.05 0.98–1.12 0.19
Male sex 0.56 0.23–1.35 0.20 0.62 0.24–1.59 0.32
Diabetes 2.66 1.14–6.21 0.02 1.55 0.60–4.04 0.37
CI, Confidence interval; OR, odds ratio.
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(41%) observed in our study is similar to another population-
based sample of elderly enrolled in the Framingham Heart Study
during the same time frame, in which 48% of individuals taking
thyroid hormone preparations had a low TSH (1), and higher
than the 22% prevalence reported in a community health fair and
the 5% prevalence in a study of an endocrine clinic population
(2, 5). In our study, participants were unaware that thyroid func-
tion tests were being performed, unlike the latter two studies. In
the study of the endocrine clinic population, inadequately con-
trolled patients demonstrated a higher age at diagnosis, consis-
tent with the higher prevalence of TSH abnormalities in our
population (5). One important consideration is that our thyroid
function test data are from a study visit conducted in 1989–
1990. It is possible that providers were less concerned about
adverse sequelae of over-replacement at that time, though the
concern over exacerbating underlying cardiac conditions in
older people has been present in the field for many years, as has
the “start low, go slow” recommendation for thyroid hormone
replacement (6). We also do not have data on the duration of
treatment, and it is likely that a proportion of those who are
over-replaced and under-replaced, though not all, were in a ti-
tration phase of therapy that would ultimately stabilize.
It has been reported that older hypothyroid patients need
approximately 25% less T4 than younger patients (7, 8). Not
only is there a decrease in the secretion of thyroid hormone with
increasing age (9, 10), but the half-life of T4 also increases with
age, with a mean half-life of 6.7 d for adults aged 18–27 yr of age,
and approximately 9 d for those aged 65 yr and older (9). To-
gether, these data suggest that older individuals should be initi-
ated on lower doses of T4 replacement and that a longer duration
may be required between dose titrations. Furthermore, continued
monitoring is necessary to assess for decreasing thyroid hormone
requirements over time. In one British study, physicians failed to
adjust the T4 dose in 89% of those with low TSH levels (11).
We sought to identify characteristics of individuals whose
TSH levels were not at goal, by examining a series of demo-
graphical and health factors that could be related to poor ad-
herence or altered thyroid hormone requirements. A dispropor-
tionate number of women was in the low TSH group compared
with the euthyroid group. Our data suggest that this difference
is due to the lower weight of women because sex was no longer
associated with low TSH after adjusting for weight. In this cross-
sectional analysis, we cannot determine whether the low weight
is a contributor to low TSH levels or a result of over-replacement
with thyroid hormone (accidental or intentional), though there
are data to support weight-based dosing of thyroid hormone
replacement (7, 12, 13).
There was no association of altered TSH levels with polyp-
harmacy or increased medical comorbidities that could alter thy-
roid hormone metabolism. In fact, the low TSH group had fewer
medical diseases and less prescription medication use, though
this effect disappeared in multivariable analyses. When we ex-
amined the association between individual diseases and low
TSH, those with renal insufficiency were less likely to be in the
low TSH group. These data suggest that there is equal or better
monitoring of thyroid hormone replacement in those with
chronic diseases and no effect of polypharmacy on the ability of
older individuals to be able to adhere to thyroid medication daily
dosing. The one exception was diabetes. In our study, both low
and high TSH levels in older individuals taking thyroid hormone
preparations were associated with an increased prevalence of
diabetes. This suggests difficulty in managing thyroid hormone
replacement in the setting of diabetes, rather than both decreased
and increased dose requirements in the diabetic population. Al-
ternatively, in the setting of multiple comparisons, this could be
a spurious finding that should be verified in other populations.
A major strength of this study is the use of a large, population-
based cohort of older men and women with a wealth of data
related to their health status. Our focus on the elderly targets the
population most likely to experience deleterious effects from
inadequate or overtreatment. In addition, we have TSH and free
T4 in a large subset of people who were not presenting for eval-
uation of thyroid disorders. However, our analyses are cross-





















































































































































































































































FIG. 1. Thyroid function tests among participants taking all types of thyroid
hormone preparations (A), only T4 preparations (B), and only T4 plus T3
preparations (C).
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sectional in nature and limit causal inference. We do not have
information on the reason for thyroid hormone prescription or
duration of therapy, and our subcategorization of overt and sub-
clinical hyperthyroidism is limited by a lack of T3 levels.
Clinical implications
Thyroid function testing abnormalities are common in elderly
men and women taking thyroid hormone replacement medica-
tion. Our data support the recommendation that older individ-
uals taking thyroid hormone preparations, especially those of
lower weight or with diabetes, be monitored for thyroid function
abnormalities. There are data to support acting on low TSH
levels, given cardiac and skeletal effects from thyroid hormone
excess that could be particularly deleterious in the elderly (1, 4,
14, 15). The prevalence of older people taking thyroid hormone
replacement who have TSH levels above 4.5 mU/liter is lower,
and may be of lesser consequence, given the large proportion of
older individuals without thyroid disease who have TSH levels in
the 6–8 mU/liter range (16) and data to suggest no adverse se-
quelae from mild TSH elevations in older people (4, 17).
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